Related Experiment Video
Updated: Apr 26, 2026
Generation of 3D Tumor Spheroids for Drug Evaluation Studies
Published on: February 24, 2023
Efficacy of S-1 in non-small cell lung cancer
1Otemae Hospital, Federation of National Public Services and Affiliated Personnel Mutual Aid Associations , 1-5-34, Otemae, Chuo-ku, Osaka, 540-0008 , Japan +81 66941 0484 ; +81 66942 2848 ; kawaharam@otemae.gr.jp.
Introduction:
S-1 is an oral fluoropyrimidine derivative, including three pharmacological compounds: tegafur, gimeracil and oteracil, in a molar ratio of 1: 0.4: 1.
Areas Covered:
This review addresses the clinical evidence of S-1 in NSCLC in various clinical settings. Currently, S-1 for NSCLC is approved only in Japan. Prospective studies of S-1 as front-line and second-line chemotherapy with or without other agents and concurrent chemoradiotherapy are mainly reviewed. Only two Phase III clinical trials were published or presented for advanced NSCLC. S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. The combination of S-1 and a platinum agent is active against NSCLC, regardless of tumor histology.
Expert Opinion:
It is becoming possible to design effective regimens with S-1 against NSCLC in various clinical settings considering the ethnic differences in pharmacokinetics and a greater understanding of the underlying molecular pathways or biomarkers of NSCLC. Further Phase III studies with S-1 for both early and advanced NSCLC are warranted worldwide.
